ECTRIMS 2025 Barcelona
Let's meet ...
Dr Wolf attends the 41st Congress of the European Committee on Treatment and Research in Multiple Sclerosis from 23-26 September 2025 at the Centre de Convencions Internacional in Barcelona.
Dr Wolf co-authored one oral presentation and three posters:
- Fox RJ, Wolf C, Nastaj M, Nehrych T, Boshkova T, Bozhinov P, Shulga O, Sciacca V, Ondrus M, Myles J, Weerage A, Ghadiri F, Muehler A. Efficacy and Safety of Vidofludimus Calcium, a Novel Nurr1 Activator and DHODH Inhibitor, in Primary Progressive Multiple Sclerosis (PPMS): Subpopulation Data from the Phase 2 CALLIPER Trial. P417 (poster).
- Fox RJ, Wolf C, Nastaj M, Nehrych T, Boshkova T, Bozhinov P, Shulga O, Sciacca V, Ondrus M, Myles J, Ghadiri F, Muehler A. Efficacy and Safety of Vidofludimus Calcium, a novel Nurr1 activator and DHODH inhibitor, in Progressive Multiple Sclerosis: Data from the Phase 2 CALLIPER Trial. O024 (presentation).
- Fox RJ, Sciacca V, Ondrus M, Sellner J, Wolf C, Myles J, Ghadiri F, Muehler A. 144-Week Analysis of the Confirmed Disability Worsening Events in the Open-Label Treatment Extension of the Phase 2 EMPhASIS Study of Vidofludimus Calcium in Patients with Relapsing Remitting Multiple Sclerosis. P814 (poster).
- Fox RJ, Dokova Y, Wolf C, Ondrus M, Sciacca V, Muehler A. Update on the Assessment of Long-Term Safety and Tolerability of Vidofludimus Calcium in Patients with Relapsing-Remitting Multiple Sclerosis in the Open-Label Extension Period of the Phase 2 EMPhASIS Trial. P834 (poster).